Panacea Biotec shares got a healthy boost, climbing nearly 5% to ₹456 after scoring a ₹127 crore (US$ 14.95 million) order from UNICEF for 115 million doses of its bivalent oral polio vaccine (bOPV). Set for delivery in 2025, these vaccines will support immunization efforts across Africa and Asia. This announcement comes as a much-needed win for the company, which recently posted a ₹4.8 crore profit for Q2 FY2024 after three straight quarters of red ink. Revenue jumped 27.18% quarter-on-quarter—the biggest leap in three years—showcasing a strong rebound in operations. Zooming out, Panacea has been a long-term performer, delivering a stellar 126.6% return over three years, outpacing the Nifty Smallcap 100’s 72.66% rise. With a market cap of ₹2,653.69 crore and nearly four decades in the pharma game, this small-cap player continues to punch above its weight. UNICEF’s nod signals more than just a business win; it’s a vote of confidence in Panacea’s capabilities on the global stage. Investors seem to agree, as the stock reflects optimism for what’s ahead.